In essential hypertension, both whether changes in LZ+ MYPT1 expression contribute to the molecular mechanism producing this disease and strategies to improve LZ+ MYPT1 expression and the sensitivity to NO-based vasodilators for the treatment of hypertension have not been investigated. The gene discussed is PPP1R12A; the disease is Hypertension.